Company intelligence / Profile preview

Ankrin Therapeutics

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Ankrin Therapeutics was a Danish biotech start-up focused on developing first-in-class drugs for cancer treatment using innovative approaches in precision oncology. The company participated in the BioInnovation Institute's Creation House incubator program. As of March 2025, the company filed for bankruptcy after five years of operation, reportedly due to financial challenges including a pandemic-era loan coming due[3][4]. There are no publicly reported clinical results or late-stage assets.

Therapeutic areas: Oncology
Modalities: Small molecules (likely)novel therapeutic strategies for cancer (specifics not detailed)
Industry: Biotech

Partnerships

Supported by BioInnovation Institute's Creation House program[4]

Beyond the preview

Go deeper on Ankrin Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ankrin Therapeutics.

Explore the full profile